These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 28163164)

  • 1. Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm.
    Rao M; Valentini D; Dodoo E; Zumla A; Maeurer M
    Int J Infect Dis; 2017 Mar; 56():221-228. PubMed ID: 28163164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoints and their inhibition in cancer and infectious diseases.
    Dyck L; Mills KHG
    Eur J Immunol; 2017 May; 47(5):765-779. PubMed ID: 28393361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the clinical development of immune checkpoint blockade therapy.
    Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
    Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Blockade in Breast Cancer Therapy.
    Bu X; Yao Y; Li X
    Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
    Goodman A; Patel SP; Kurzrock R
    Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint blockade in infectious diseases.
    Wykes MN; Lewin SR
    Nat Rev Immunol; 2018 Feb; 18(2):91-104. PubMed ID: 28990586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Blockade in Cancer Therapy.
    Postow MA; Callahan MK; Wolchok JD
    J Clin Oncol; 2015 Jun; 33(17):1974-82. PubMed ID: 25605845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitors for cancer treatment.
    Park J; Kwon M; Shin EC
    Arch Pharm Res; 2016 Nov; 39(11):1577-1587. PubMed ID: 27770382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint blockade: a common denominator approach to cancer therapy.
    Topalian SL; Drake CG; Pardoll DM
    Cancer Cell; 2015 Apr; 27(4):450-61. PubMed ID: 25858804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
    Hamanishi J; Mandai M; Matsumura N; Abiko K; Baba T; Konishi I
    Int J Clin Oncol; 2016 Jun; 21(3):462-73. PubMed ID: 26899259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment].
    Passat T; Touchefeu Y; Gervois N; Jarry A; Bossard C; Bennouna J
    Bull Cancer; 2018 Nov; 105(11):1033-1041. PubMed ID: 30244981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.
    Moreno-Cubero E; Larrubia JR
    World J Gastroenterol; 2016 Jul; 22(28):6469-83. PubMed ID: 27605882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.